Skip to main content
Premium Trial:

Request an Annual Quote

Biomax Expands Agreement with Royal DSM to Include Synthetic Biology Solutions

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biomax Informatics today said that it has expanded its licensing and services agreement with Royal DSM to include solutions for synthetic biology using the BioXM Knowledge Management Environment system.

BioXM is a software platform for dynamic modeling, visualization, and analysis of biological and biomedical networks. It enables an agile process for the development of new life sciences applications and the quick deployment of new solutions to large user communities, Biomax said.

Biomax and Royal DSM have been collaborating since 1998, and Royal DSM had early access to the next-generation BioXM system. BioXM version 4 was released in March and has a customizable web portal builder that enables quick publishing of BioXM-based application on the Internet.

Based in Planegg, Germany, Biomax develops software solutions for life science applications. Royal DSM is a life science and materials science firm headquartered in Heerlen, the Netherlands.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.